Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

By Nikita Chaurasia  | Date: 2021-01-04

Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

Indian pharmaceutical company Cadila Healthcare Limited, commonly known as Zydus Cadila, has made it to the headlines after receiving the approval of the DCGI (Drugs Controller General of India) for the Phase 3 clinical trials of its Coronavirus vaccine ZyCoV-D.

For the uninitiated, ZyCoV-D is a plasmid DNA, which translates into viral proteins when introduced into the host cells in order to trigger a robust immune response, facilitated by the humoral and cellular arms of the human immune system.

The Phase 3 trial round will include around 30000 volunteers. Sources confirmed that the company plans on initiating the launch as well as administration of the vaccine in the first quarter of the next financial year if the trial results are in its favor.

Reportedly, ZyCoV-D was proven to be well-tolerated, safe and immunogenic in its phase-1 and phase-2 clinical trials. It is also worth mentioning that the phase-2 trial round was conducted on around 1000 volunteers and included a randomized, multi-centric, dose-escalation double-blind placebo-controlled study.

The phase-2 trials were reviewed by an independent DSMB (Data Safety Monitoring Board) and the reports of the safety outcomes were submitted to the CDSCO (Central Drugs Standard Control Organization). Zydus Cadila then called for the DCGI approval after the phase-2 trials concluded positive outcomes.

Chairman of Zydus Group, Pankaj Patel was reported saying that the DCGI approval marks a significant milestone for the company’s vaccine development program. The phase-3 trials will ascertain the efficacy of ZyCoV-D in the treatment of Covid-19, he added.

The introduction of ZyCoV-D, developed in the company's Ahmedabad-based Vaccine Technology Centre, has paved the way for the establishment of a DNA vaccine platform in India, sources claimed. This platform has proven to improve vaccine stability and hence requires lower cold chain storage.

Moreover, Zydus Cadila has reportedly employed around 300 scientists to conduct comprehensive research on the vaccine, with around 1,400 researchers working on pharmaceutical technologies, biologicals and chemical entities (NCEs).

Source credits –

https://www.business-standard.com/article/current-affairs/zydus-gets-dcgi-nod-for-conducting-phase-3-clinical-trials-of-zycov-d-121010300466_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...